Send to

Choose Destination
Clin Invest Med. 2009 Dec 1;32(6):E315.

Prognostic value of CRM1 in pancreas cancer.

Author information

Department of Oncology, Affiliated People's 1st Hospital, Shanghai Jiaotong University, Shanghai, PR China 200085.



Pancreatic cancer is a highly aggressive malignant tumour with poor prognosis. The median survival is only 6 months. This study investigated the prognostic value of nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 (CRM1) expression in pancreas cancer.


CRM1 expression was detected, by Western blot, in pancreatic tissue from 69 cancer patients and 10 normal subjects.


CRM1 showed increased expression in pancreatic cancer tissue (P = 0.007). The high expression of CRM1 was associated with increased serum levels of CEA (P = 0.002) and CA19-9 (P = 0.005). There was an association between CRM1 expression and tumour size (P = 0.01), lymphadenopathy (P = 0.004) and liver metastasis (P = 0.003). High CRM1 expression was not correlated with the other clinicopathological parameters. High CRM1 expression was a prognostic indicator for progression-free survival (PFS) (P = 0.006) as well as overall survival (OS) (P = 0.001). Expression of CRM1 was an independent prognostic parameter for poorer PFS and OS (95% CI, 1.27-5.39).


CRM1 expression demonstrated prognostic value in pancreatic cancer. Prospective studies are required to determine the prognostic role of high expression of CRM1 in pancreatic cancer.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center